LDL Hyperlipoproteinemia

Periodontitis is a chronic, multifactorial inflammatory disease primarily caused by dysbiotic plaque biofilms, characterized by the progressive destruction of the supporting structures of the teeth. In advanced stages (Stage III/IV), periodontitis leads to significant attachment and bone loss, often culminating in tooth loss and a negative impact on the patient's quality of life. Recent evidence has emphasized the systemic implications of periodontal inflammation, suggesting a bidirectional relationship between periodontitis and various systemic conditions, especially cardiovascular diseases

The pharmacological reduction of LDL-C lowers cardiovascular risk and is therefore a priority in cardiovascular secondary prevention. The achievement of LDL-C target levels in Germany, Europe, and worldwide is inadequate, despite a wide array of lipid-lowering medications. Only a small proportion of post-myocardial infarction patients reach their LDL-C target range within a year. There is a significant need for new strategies to improve LDL-C target achievement and thereby reduce the occurrence of secondary cardiovascular events. The aim of the study is to establish a basis for improving prevention by achieving the target LDL level effectively and quickly in patients with high and very high cardiovascular risk profiles.